ArticleMolecular cancer2026
m6A-dependent translation of circPICALM encodes a novel metastasis-promoting oncoprotein in intrahepatic cholangiocarcinoma.
Article in Molecular cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Emerging strategies and innovations in circular RNA synthesis.Molecular therapy. Nucleic acids · 2026Review
- Comprehensive characterization of SLC41A3 identifies it as an immune-related prognostic biomarker and therapeutic target in hepatocellular carcinoma.Frontiers in immunology · 2026Article
- Multi-omics and spatial transcriptomics decode the ZDHHC9-driven hypoxia-immunosuppressive axis in hepatocellular carcinoma.Frontiers in oncology · 2026Article
- Metabolic Reprogramming-Targeted Therapeutic Strategies in Primary Liver Cancer: A Bibliometric and Visualized Analysis.Journal of hepatocellular carcinoma · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundIntrahepatic cholangiocarcinoma (ICC) is a highly aggressive liver cancer with a poor prognosis and rapid metastatic potential. Although circular RNAs (circRNAs) have emerged as important regulators in cancer biology, their translational potential and mechanistic contributions to ICC metastasis remain largely unexplored.
methodsCircRNA-seq was performed on paired primary and recurrent ICC tissues to identify the differentially expressed circRNAs. Mass spectrometry and functional assays were used to characterize the novel protein encoded by circPICALM. The molecular mechanisms and biological functions of circPICALM and its encoded proteins were evaluated using in vitro and in vivo models, respectively.
resultsCircPICALM is significantly upregulated in recurrent ICC tumors and is associated with poor patient prognosis. Its biogenesis and expression are regulated by N6-methyladenosine (m6A) modifications within the introns flanking the circulating exons, facilitated by the m6A reader protein YTHDC1. Additionally, the RNA-binding protein, DEAD-box helicase 3 (DDX3), promotes circPICALM accumulation. Importantly, circPICALM encodes a novel protein, circPICALM-219aa, that drives ICC metastasis. Mechanistically, circPICALM-219aa disrupted the inhibitory interaction between SOCS3 and STAT3 by directly binding to both proteins. This interference alleviates SOCS3-mediated suppression of JAK activity and enhances IL-6/JAK/STAT3 signaling. Silencing circPICALM-219aa expression significantly suppressed the activation of this signaling pathway and metastatic potential.
conclusionsThis study identified circPICALM-219aa as a novel oncoprotein translated from an m6A-modified circRNA, and a key driver of ICC metastasis. Our findings uncover a previously unrecognized mechanism of m6A-mediated circRNA translation in ICC and highlight circPICALM-219aa as a promising therapeutic target for improving patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.